Email this article 
Post a Comment Phospholipids particles inhalation in therapy of asthma: randomized placebo-controlled trial
- Authors: Lisitsa A.V.1, Averyanov A.V.1, Sodaeva S.K.2, Klimanov I.A.2, Mikhailov S.E.3
-
Affiliations:
- FSBI "Federal Scientific and Clinical Center for the Provision of Specialized Types of Medical Aid and Medical Technologies" FMBA of Russia
- Federal State Institution "Research Institute of Pulmonology" FMBA of Russia
- NUZ "Central Clinical Hospital № 1 of JSC" Russian Railways "
- Issue: Vol 3, No 1 (2012)
- Pages: 15-22
- Section: Original Study Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/83813
- DOI: https://doi.org/10.17816/clinpract83813
- ID: 83813
Cite item
Full Text
Abstract
The prospective single-blind randomized placebo-controlled study was performed.
The aim of the study was to investigate the effectiveness and safety of phospholipids' particles inhalation in patients with bronchial asthma. The results obtained demonstrate the statistically significant improvements both in clinical status and lung function tests. No any clinically significant adverse events were registered.
Full Text
##article.viewOnOriginalSite##About the authors
Alexander V. Lisitsa
FSBI "Federal Scientific and Clinical Center for the Provision of Specialized Types of Medical Aid and Medical Technologies" FMBA of Russia
Author for correspondence.
Email: afox03@mail.ru
Head of Clinical Research Department, Candidate of Medical Sciences
Russian Federation, MoscowAlexander V. Averyanov
FSBI "Federal Scientific and Clinical Center for the Provision of Specialized Types of Medical Aid and Medical Technologies" FMBA of Russia
Email: averyanovav@mail.ru
Deputy General Director for Research, Doctor of Medical Sciences
Russian Federation, MoscowSvetlana K. Sodaeva
Federal State Institution "Research Institute of Pulmonology" FMBA of Russia
Email: soodaeva@mail.ru
Head of the Laboratory of Experimental and Clinical Biophysics, Doctor of Medical Sciences, Professor
Russian Federation, MoscowIgor A. Klimanov
Federal State Institution "Research Institute of Pulmonology" FMBA of Russia
Email: igorrlimanov@yandex.ru
Researcher, Laboratory of Experimental and Clinical Biophysics, Candidate of Medical Sciences
Russian Federation, MoscowSergey E. Mikhailov
NUZ "Central Clinical Hospital № 1 of JSC" Russian Railways "
Email: afox03@mail.ru
head of the pulmonary department, doctor of the highest category
Russian Federation, MoscowReferences
- Global Initiative for Asthma, National Institute of Health, National Heart Lung and Blood Institute, NHLBI/WHO Workshop report. Global strategy for asthma management and prevention. NHLBI/WHO workshop report 02-3659. January 1995, revised 2010.
- Fireman P., Prenner B., Vincken W. et al. Longterm safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol Ann Allergy Asthma Immunol 2001; 86(5): 557-65.
- Suissa S., Ernst R., Benayoun S. et al. Low-dose inhaled corticosteroids and the prevention of death from asthma N Engl J Med 2000; 343(5); 332-336.
- Pauwels R.A., Löfdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997; 337(20): 1405-1411.
- Fardon T.C., Burns P., Barnes M.L., Lipworth B.J. et al. A comparison of 2 extrafine hydrofluoroalkane- 134a-beclomethasone formulations on methacholine hyperresponsiveness. Ann Allergy Asthma Immunol. 2006; 96(3): 422-430.
- Lazarus S.C., Boushey H.A., Fahy J.V. et al. Longacting ß2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. Jama. 2001; 285 (20): 2583-2593.
- Bateman E.D., Bousquet J., Busse W.W. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170(8): 836-844.
- Godard P., Greillier P., Pigearias B. et al. Mantaining asthma control in persistent asthma: Comparison of three strategies in a 6-month doubleblind randomised study. Respiratory Medicine. 2008; 102: 1124-1131.
- Tampo Y. Studies on membrane factors in iron supported lipid peroxidation. Yakugaki Zasshi. 2000; 120: 387-396.
- Bergamini C.M., Hunte C. Lipids in membrane protein structures. Biochem Biophys Acta. 2004; 1666: 2-18.
- Ипатова O.M. Фосфоглив: механизм действия и применение в клинике. М„ 2005.
- Владимиров Ю.А., Арчаков А.И. Перекисное окисление .липидов в биологических мембранах. М.: Наука, 1972. 252с.
- Лисица А.В., Соодаева С.К., Климанов И.А., Чучалин А.Г. Динамика показателей окислительного стресса у больных, переносящих обострение бронхиальной астмы, на фоне ингаляционной терапии липосомальными препаратами. Пульмонология. 2010; 1: 74-80.
- Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur Respir J. 2005; 26: 319-338.
Supplementary files
